Biologic Drugs and Biosimilars – Here’s What You Need to Know

Biologic drugs can be life saving when plan members or their dependents become ill, but they can also be incredibly expensive, driving up the cost of your benefits plan. But what if there was a less expensive, yet highly effective solution?

That’s where biosimilar drugs come in. Biosimilars offer similar benefits as their native biologic, but at a fraction of the cost.

What Are Biosimilars?

Biologics tend to be larger and more complex than chemically made pharmaceuticals. They’re also more natural, as they are composed of living organisms.

According to Health Canada, a biosimilar is “a biologic drug that enters the market after a previously authorized brand version in Canada and with a demonstrated similarity to that reference biologic drug.” Due to the complex nature of biologics, biosimilars can only be “similarly” related to the original biologic – they’re not the exact same.

Biosimilars have gained widespread attention in recent years as a lower cost alternative to the original biologic drug. Many Insurer’s have increased the uptake of biosimilars through a biosimilar transition program. Under the Insurer’s formularies, biosimilars are listed as preferred products, and the originator products are covered only in exceptional circumstances. This allows easier access to the less expensive biosimilars to plan members.

Why are Biosimilars not Being Used All the Time?

If biosimilars are cheaper and do the exact same thing, why aren’t more people using them? It comes down to two big reasons (although there are others):

  • Stigma and misinformation. The perception of a biosimilar has proven difficult to overcome. Many ask, “Is similar good enough?” The other difficulty to overcome is the idea that if it’s cheaper, that must mean it’s not as effective or has added side effects.

  • Physician reluctance to prescribe. Biosimilars are still relatively new to the market when compared to their biologic counterparts. Physicians have been hesitant in adopting these new drugs because of their familiarity with biologics and the effects on their patients.

Both of these issues will take time to correct, but as insurers  continue to promote the benefits of biosimilars and stay the course with the transition program, uptake is expected to increase.

The Biosimilar Transition Program

A program based on evidence…

One such leader in Transitioning to Biosimilar’s is Green Shield Canada. Since introducing their biosimilar standard, GSC has been closely monitoring the emerging scientific evidence examining the safety and efficacy of transitioning from an originator biologic product to the biosimilar counterpart.

The evidence GSC have garnered has rapidly accumulated over the last two years, and it is all pointing in the same direction: patients can safely transition from an originator biologic to a biosimilar product with no loss of clinical benefit and no compromise in safety. Over 1,500 patients have now been involved in 13 transition studies, conducted across 11 countries. This is a staggering amount of evidence that outpaces the evidence available for any new drug entering the market today. In addition to the robust clinical-trial evidence, there is also a tremendous amount of “real-world” data emerging from Europe, where biosimilars have been available since 2006. This evidence is complementary and supports the clinical trial information.

Taken together, all the evidence strongly supports safe and effective patient transitioning to biosimilars.

The employee experience…

The program is expressly designed with a strong support system to help employee’s transition from an originator product to a corresponding biosimilar by working closely with a dedicated team of care-coordinator nurses who will assist patients with the transition process.

Employee’s currently taking one of the targeted conditions will be sent a letter explaining the program, the evidence for transitioning, and next steps. The letter outlines the two available options:

  1. To go ahead with a one-time transition to the biosimilar after discussing it with their doctor.


  1. To continue treatment with the originator biologic and pay the difference in cost between the two products.

    Employee’s who decide to transition to the biosimilar are directed to call a dedicated phone line staffed by a care-coordinator nurse who will guide patients through the transition process.



Related Posts

Covid Travel Updates

What the new government announcements mean for you. COVID-19 measures at the border are being eased. So what does that mean for you? Here’s what you need to know.  On February 28th the global avoid “non-essential travel” advisory will be lifted. Please keep in mind coverage is not provided in destinations that the Federal Government has issued an […]

Changes to the GAINS Benefit Rate Tables

Benefit period: April 1, 2019 to June 30, 2019 The GAINS rate tables have been updated to provide a ready reference of OAS/GIS/GAINS payments at specified levels of private income, depending on a senior’s status e.g., single or couple. Guaranteed Income Supplement Single pensioners: $1,582.77 monthly ($18,993.24 annually) Qualified couples, per person: $1,225.22 monthly ($14,702.64 annually) Read all about GAINS […]

Cost Plus

Cost Plus coverage provides designated plan members and their dependents with additional benefits for expense items that aren’t covered and for items that exceed current coverage amounts identified in the benefits program. Under a Cost Plus program, a Cost Plus claim is an expense that is an eligible drug, dental or extended health claim under the Canadian […]

Registered Pension / Savings Plan

Individual contributions to Registered Retirement Savings Plans (RRSP) and Registered Pension Plans (RPP) are tax deductible and not taxed until the funds are withdrawn. For RRSP and RPP plans, there is a maximum amount for what you can deposit in a given year. Tax-Free Savings Accounts (TFSA) are a government-regulated tax-free savings plan. Similar to the RRSP […]

Group benefit taxation

Each benefit, depending on what your employer provides, plus the percentage you pay versus the percentage your employer pays – makes it a taxable or a non-taxable benefit. Taxable Income Premium is a tax deductible expense (Employer) Employer contributions?1 Benefit payments to employee Group Life yes Taxable Benefit Non-Taxable Dependent Life yes Taxable Benefit Non-Taxable Wage-Loss Replacement […]

Workers’ Compensation Maximum assemble earnings subject to premiums

Workers compensation (WCIB) is a percentage of earnings that you are required to pay out of your paycheck if you ever need to draw on it. Maximum assessable earnings subject to premiums. Taxable Income 2018 2019 British Columbia $82,700 $84,800 Alberta $98,700 $98,700 Saskatchewan $82,627 $88,314 Manitoba $127,000 $127,000 Ontario $90,300 $92,600 Quebec $74,000 $76,500 New Brunswick […]

Ontario Individual Health Premiums

Ontario residents pay the health premium through the income tax system. The money collected through the tax funds Ontario’s health services. Taxable Income 2005 and later tax years $0.00 – $20,000 no premium $20,001 – $25,000 (taxable income – $20,000) x 6% $25,000 – $36,000 $300 $36,001 – $38,500 $300 + (taxable income – $36,000) x 6% […]

Canada Pension Plan (CPP)

The CPP provides retirement benefits to people who have worked and contributed to the plan. The CPP supplements your retirement savings plan. Contributions towards CPP are deducted from the individual’s pay. This chart specifies annual contribution limits for individuals based on the Canada Revenue Agency (CRA) guidelines. Benefits – CPP 2018 Max. Amount 2019 Max. Amount Retirement […]